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Summary Objective: We explored if HIV infection is associated with impaired T-Helper 17
responses against Streptococcus pneumoniae in the lung.
Methods: We recruited 30 HIV-uninfected healthy controls, 23 asymptomatic HIV-infected
adults not on ART, and 40 asymptomatic HIV-infected adults on ART (Median time 3.5yrs), in
whom we collected bronchoalveolar lavage ﬂuid. We measured alveolar CD4+ T cell immune
responses following stimulationwith pneumococcal cell culture supernatant using ﬂow cytometry-
based intracellular cytokine staining.
Results: We found that the proportion of alveolar CD4+ T cells producing IL-17A following
stimulation with pneumococcal cell culture supernatant (CCS) was similar between HIV-
uninfected controls and ART-naïve HIV-infected adults (0.10% vs. 0.14%; p = 0.9273). In contrast,
the proportion and relative absolute counts of CD4+ T cells producing IL-17A in response to
pneumococcal CCS were higher in ART-treated HIV-infected adults compared HIV-uninfected
controls (0.22% vs. 0.10%, p = 0.0166; 5420 vs. 1902 cells/100 ml BAL ﬂuid; p = 0.0519). The
increase in relative absolute numbers of IL-17A-producing alveolar CD4+ T cells in ART-treated
individuals was not correlatedwith the peripheral blood CD4+ T cell count (r=–0.1876, p = 0.1785).
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Conclusion: Alveolar Th17 responses against S. pneumoniae are preserved in HIV-infected
adults. This suggests that there are other alternative mechanisms that are altered in HIV-
infected individuals that render them more susceptible to pneumococcal pneumonia.
© 2017 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.
This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
Introduction
Invasive pneumococcal disease (IPD), in the form of pneu-
monia and bacteraemia is a leading cause of mortality
worldwide.1,2 HIV-infected adults are 60 times more likely to
suffer IPD than age-matched HIV-negative persons.3–5 Initia-
tion of antiretroviral therapy (ART) has led to a reduction in
the incidence of IPD in HIV-infected individuals.4 Neverthe-
less, the risk of pneumococcal pneumonia is still 30-fold
higher in HIV-infected persons on ART compared to HIV-
uninfected individuals.6,7 It is not clear what factors are
behind the persistent high risk of pneumococcal pneumonia
in HIV-infected individuals on ART.
We have previously shown that IFN-γ- and TNF-producing
alveolar CD4+ T cell responses to Streptococcus pneumoniae
are maintained in asymptomatic chronic HIV-infected
individuals.8 This suggested that the increased risk to pneu-
mococcal pneumonia in these individuals might not be due
to depletion of these important CD4+ T cell subsets in the
alveoli. Recently, IL-17A-producing CD4+ T cells in the lung
have been shown to be critical in conferring protection in
murinemodels of pneumococcal lung infection.9,10 In humans,
our data from an experimental pneumococcal nasal carriage
model showed that pneumococcal carriage leads to increased
frequency of pneumococcal-speciﬁc Th17 cells in the lung,
and that alveolar macrophages exhibited enhanced killing of
opsonised pneumococci upon stimulation with recombinant
human IL-17A.11 Furthermore, children that are prone to
acute otitis media have been shown to have reduced prolif-
eration and differentiation of pneumococcal-speciﬁc IL-17A-
producing CD4+ T cells in peripheral blood compared with
non-infection prone children.12 Taken together, these studies
suggest that Th17 cells may play an important role in con-
ferringprotectionagainstmucosal infection in adults.However,
the link between pneumococcal-speciﬁc Th17 immunity and
increased risk of pneumococcal pneumonia in HIV-infected
individuals has not yet been substantiated.
We therefore explored the possibility that Th17 responses
against S. pneumoniae in the lung are impaired in HIV-
infected adults and are not reconstitutedwith ART.We deter-
mined the proportion of alveolar CD4+T cells producing IL-17A,
TNF and IFN-γ after stimulationwith pneumococcal cell culture
supernatant (CCS), in HIV-uninfected controls compared
to untreated or ART-treated asymptomatic HIV-infected
adults.
Results
Participant characteristics
We recruited 30 HIV-uninfected healthy controls (median
age [range] 39[18–44]; male:female, 22:8) and 63 asymp-
tomatic HIV-infected adults (median age [range] 32[20–46];
male:female,16:47), 23 of whom were ART-naive and 40
were receiving ART (median time on ART [range] 3.5yrs [0.7–
9.8]). Two-thirds (30/40) of the ART-treated participants
were receiving stavudine/lamivudine/nevirapine therapy,while
one-third (10/40) were on tenofovir/lamivudine/efavirenz
therapyaccording tonational treatment guidelines. Theperiph-
eral blood CD4 count of the ART-naïve HIV-infected adults
was lower than that of HIV-uninfected controls (399 vs. 818
cells/µl, p < 0.0001). Similarly, the peripheral blood CD4
count of the ART-treated HIV-infected adults was lower than
that of HIV-uninfected controls (450 vs. 818 cells/µl,
p < 0.0001). However, the peripheral blood CD4 count of the
ART-naïve HIV-infected adults was not statistically signiﬁ-
cantly different from ART-treated HIV-infected adults, but
the viral load was lower in the ART-treated HIV-infected
adults, with 85% (34/40) of the individuals having a plasma
HIV viral load of <150 copies/ml. The main characteristics of
the participants are summarized in Table 1.
Alveolar CD4+ T cell cytokine responses against S.
pneumoniaeare preserved in HIV-infected adults
Flowcytometry-based intracellular cytokine staining for IL-17A,
TNF and IFN-γ was used to detect CD4+ T cell responses
following stimulation of BAL cells with pneumococcal cell
culture supernatant (Fig. 1). We found comparable propor-
tions of IL-17A-producing alveolar CD4+ T cells between ART-
naïve HIV-infected adults andHIV-uninfected controls (Median
0.14% [Interquartile range 0.05–0.30] vs. 0.10% [0.02–0.20];
p = 0.9273) (Fig. 2A). Similarly, there were no signiﬁcant
differences in the proportions of TNF- and IFN-γ-producing
alveolar CD4+ T cells between ART-naïve HIV-infected adults
andHIV-uninfected controls (0.31% [0.05–0.78] vs. 0.10%[0.05–
0.34]; p = 0.5206 and 0.51% [0.15–1.48] vs. 0.37%[0.12–
0.90]; p > 0.9999, respectively) (Fig. 2B and 2C).
ART is associated with increased proportion of
IL-17A/ TNF-producing alveolar CD4+T cells against
S. pneumoniaein HIV infected adults
We then investigated the impact of ART on IL-17A, TNF and
IFN-γ-producing alveolar CD4+ T cells, by stimulating BAL
cells obtained from ART-treated HIV-infected adults with
pneumococcal CCS and determining the proportions of the
responding cells using ﬂow cytometry-based intracellular
cytokine staining. We found that the proportion of IL-17A-
producing alveolar CD4+ T cells was higher in ART-treated
HIV-infected adults compared to HIV-uninfected individuals
(Median 0.22% [Interquartile range 0.08–0.50] vs. 0.10%[0.02–
0.20]; p = 0.0166) (Fig. 2A). Similarly, the proportion of
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TNF-producing alveolar CD4+ T cells was higher in ART-
treated HIV-infected adults compared to HIV-uninfected indi-
viduals (0.51% [0.18–1.16] vs. 0.10%[0.05–0.34]; p = 0.0032)
(Fig. 2B). In contrast, there was no statistically signiﬁcant
difference in proportion of IFN-γ-producing alveolar CD4+ T
cells between ART-treated HIV-infected adults and HIV-
uninfected individuals (0.57% [0.16–1.51] vs. 0.37%[0.12–
0.90]; p = 0.2664) (Fig. 2C).
Table 1 Demographics of study participants.
HIV-uninfected
(n = 30)
HIV-infected
ART-naive (n = 23)
HIV-infected on
ART (n = 40)
Age (years), median (range) 29(18–44) 30(20–44) 34(20–46)
Sex (M:F) 22:8 8:15 8:32
BAL lymphocyte count (cells/100 ml BAL ﬂuid),
median (IQR)
5.8x106(3.6–11.7x106) 8.7x106(4.9–17.5x106) 8.3x106(5.2–16.2x106)
BAL CD4 count (cells/100 ml BAL ﬂuid), median (IQR) 2.9x106(1.5–5.9x106) 2.8x106(1.9–5.2x106) 2.3x106(1.5–5.0x106)
Peripheral blood CD4 count (cells/µl), median (IQR) 818(668–964) 399(244–556) 450(321–640)
Plasma viral load (copies/ml), median (IQR) N/A 33944(3364–289733) a4476(607–198088)
Years on cART, median (range) N/A N/A 3.5(0.7–9.8)
a This is for 6 out of 40 ART-treated HIV-infected individuals (the remaining 34 had plasma HIV viral load of <150 copies/ml, the lower
limit of detection of the assay).
IQR, interquartile range; N/A, not applicable.
Figure 1 Representative ﬂow cytometry dot plots showing pneumococcal-speciﬁc alveolar CD4+ T cell responses in BAL ﬂuid from
a healthy HIV-uninfected adult. Non-adherent bronchoalveolar lavage (BAL) cells were stimulated overnight with PMA/Ionomycin and
pneumococcal cell culture supernatant (Pneumo CCS) for 18 hours and CD4+ T cell responses were measured by intracellular cytokine
staining. The dot plots were obtained by gating on singlets, lymphocytes, live cells, CD3+ cells, CD4+ cells and combination of three
cytokines. The plots show the frequency of interferon-γ (IFN-γ), Tumor Necrosis Factor (TNF) and/or IL-17A-producing CD4+ T cells
in BAL, in non-stimulated negative control and cells stimulated with PMA/Ionomycin (Positive control), and pneumococcal cell
supernatant antigens.
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No association between the absolute numbers of
IL-17A-producing alveolar CD4+T cells and total
CD4+T cell count in BAL ﬂuid in HIV-infected adults
We then investigatedwhether the higher frequencies of IL-17A
and TNF-producing alveolar CD4+ T cells were correlated
with ART-driven reconstitution of total CD4+ T cells. First,
we determinedwhether the increase in IL-17A/TNF-producing
alveolar CD4+ T cells was not only qualitative but also quan-
titative, by comparing the relative absolute counts of the
responding T helper cells among the groups. Using the pro-
portions of IL-17A/TNF/IFN-γ-producing alveolar CD4+ T cells
in Fig. 2, we derived their relative absolute counts from the
total count of alveolar CD4+ T cells (Table 1). We found that
the relative absolute counts of IL-17A-producing alveolar
CD4+ T cells was higher in ART-treated HIV-infected adults
compared to HIV-uninfected individuals (Median 5420 cells/
100 ml BAL ﬂuid [Interquartile range 1829–15286] vs. 1902
[67–8758]; p = 0.0519) (Fig. 3A). Similarly, the relative abso-
lute counts of TNF-producing alveolar CD4+ T cells was higher
inART-treatedHIV-infectedadults compared toHIV-uninfected
individuals (11918 cells/100ml [3182–38405] vs. 3808 [1376–
18461]; p = 0.0422) (Fig. 3B). In contrast, there was no
statistically signiﬁcant difference in relative absolute counts
of IFN-γ-producing alveolar CD4+ T cells between ART-treated
HIV-infected adults and HIV-uninfected individuals (11837
cells/100ml [3680–37017] vs. 12415[3261–30270]; p = 0.4393)
(Fig. 3C). Furthermore, there was no association between
Figure 2 Proportion of cytokine-producing alveolar CD4+ T cells after stimulation with pneumococcal cell culture supernatant. BAL
cells were stimulated with pneumococcal cell culture supernatant and cytokine-producing cells were enumerated by ﬂow cytometry-
based intracellular cytokine staining. Each data point represents the proportion of A) IL17A-, B) TNF- and C) IFN-γ-producing alveolar
CD4+ T cells after subtracting background responses obtained from the non-stimulated controls. The horizontal bars represent
median. Data were analyzed using Kruskal-Wallis test and Dunn’s multiple comparisons test (HIV-, n = 30; HIV+ ART naive, n = 22; HIV+
ART+, n = 40). Pneumo CCS, pneumococcal cell culture supernatant.
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plasma viral load and the alveolar CD4+ T cell responses in
HIV-infected individuals (p = 0.5644, r = 0.1371).
Lastly, we determined whether there was an association
between the relative absolute counts of IL-17A/TNF-producing
alveolar CD4+ T cells and peripheral blood CD4 count in the
ART-treated and untreated HIV-infected adults. We did not
ﬁnd any statistically signiﬁcant correlation between the rel-
ative absolute counts of IL-17A/TNF-producing alveolar CD4+
T cells with peripheral blood CD4 count (IL-17A, r=–0.1876,
p = 0.1785; TNF, r=–0.1689, p = 0.2267).
HIV infection is associated with minimal disruption
of polyfunctional responses of cytokine-producing
alveolar CD4+T cells against S. pneumoniae
Next, we investigated whether there were any functional
differences in the Th1 and Th17 responses against S.
pneumoniae among the HIV-uninfected controls, ART-naïve
and ART-treated HIV-infected adults. We determined the
impact of HIV and ART on the Th1 and Th17 response as
previously described.13 The analysis allowed identiﬁcation of
7 different functional subsets namely; IFN-γ+TNF+IL17+,
IFN-γ+TNF+IL17-, IFN-γ+TNF-IL17+, IFN-γ-TNF+IL17+, IFN-γ+TNF-
IL17-, IFN-γ-TNF+IL17- and IFN-γ-TNF-IL17+ cells. We found that
there were no differences in the composition of total CD4+ T
cell responses against pneumococcal antigens between the
HIV-uninfected controls and ART-naive HIV-infected adults,
but therewere differences between ART-treatedHIV-infected
adults and HIV-uninfected controls or ART-naïve HIV-infected
adults (Fig. 4A). Speciﬁcally, the relative contribution of
pneumococcal-speciﬁc IFN-γ+ CD4+ T cells single producers in
the total response was lower in ART-treated HIV-infected
adults compared to HIV-uninfected controls (35% vs. 50%,
p = 0.024) (Fig. 4B and 4C). The relative contribution of
pneumococcal-speciﬁc IFN-γ+TNF+CD4+ T cells double
Figure 3 Relative absolute counts of cytokine-producing alveolar CD4
+
T cells after stimulation with pneumococcal cell culture
supernatant. Using the proportions of IL-17A/TNF/IFN-γ-producing alveolar CD4+ T cells responding to stimulation with
pneumococcal cell culture supernatant, we derived their relative absolute counts from the total count of alveolar CD4+ T
cells. Each data point represents the relative absolute count of A) IL17A-, B) TNF- and C) IFN-γ-producing alveolar CD4+ T cells.
The horizontal bars represent median. Data were analysed using Mann Whitney U test (HIV-, n = 30; HIV+ ART naive, n = 22;
HIV+ ART+, n = 40).
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Figure 4 Functional proﬁle of alveolar CD4 T cells after stimulation with pneumococcal cell culture supernatant. Cells were
analysed by ﬂow cytometry for IFN-γ, TNF, and IL-17A production by the CD4+ T cell population. Data are shown as relative
distribution of IFN-γ, TNF, and IL-17A producing CD4+ T cell subsets within the total response. A) Heat map showing the mean
distribution across subjects of different antigen-speciﬁc cytokine-producing CD4+ T cell subsets within the total response. B) Bar
charts represent the mean and standard error of the mean (SEM) of the contribution of the indicated subset (x-axis) towards the total
antigen-speciﬁc CD4+ T cell response against the indicated participant groups (color coded as shown). C) Relative distribution of
subsets within the total response which are statistically signiﬁcant among the study groups. Data were analysed using using student
t test. (HIV-, n = 30; HIV+ ART naive, n = 22; HIV+ ART+, n = 40).
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producers in the total response was lower in ART-naive HIV-
infected adults compared to ART-treated HIV-infected adults
(2% vs. 6%, p = 0.028) (Fig. 4B and 4C). The relative contri-
bution of pneumococcal-speciﬁc IL17+TNF+CD4+ T cells double
producers in the total response was higher in ART-treated
HIV-infected adults compared to HIV-uninfected individuals
(15% vs. 5%, p = 0.004) (Fig. 4B and 4C). These ﬁndings
suggest that pneumococcal-speciﬁc polyfunctional alveolar
CD4+ T cell responses areminimally impacted byHIV infection.
Discussion
We explored whether Th17 responses against S. pneumoniae
in the lung are impaired in HIV-infected individuals. We found
preserved IL-17A/TNF/IFN-γ CD4+ T cell immune responses
in ART-naïve HIV-infected adults, increased proportions and
relative absolute counts of IL-17A/TNF-producing CD4+ T cells
in BAL cells from ART-treated HIV-infected adults following
stimulation with pneumococcal CCS.
This lack of perturbation in the CD4+ T cell responses of
the lung against S. pneumoniae supports our previous ﬁnd-
ings that TNF-/IFN-γ-producing alveolar CD4+ T cell responses
are not impaired in asymptomatic HIV-infected adults.8 This
mucosal response appears compartmentalised13,14 as we have
previously shown that pneumococcal-speciﬁc CD4+ T cell
responses from the systemic circulation are impaired in HIV-
infected adults15 and not fully reconstituted following ART.16
However, even though the IL-17A/TNF/IFN-γ producing alveo-
lar CD4+ T cell responses against S. pneumoniae in HIV-
infected adults are preserved, there are other immune
processes in the alveolar space that have been shown to be
compromised in ART-naïve HIV-infected adults, which can
lead to an increased risk to lower respiratory tract infec-
tions. HIV infected adults have been shown to have impaired
alveolar macrophage proteolytic function,17 poor lung IgG
opsonic function,18 dysregulated alveolar cytokine networks19
and lymphocytic alveolitis,20,21 which could mask the poten-
tial beneﬁcial effects of the local alveolar CD4+T cell responses
against S. pneumoniae.
Interestingly, the proportions of IL-17A and TNF-producing
alveolar CD4+ T cells responding to pneumococcal stimula-
tion were higher in ART-treated HIV-infected adults com-
pared to HIV-uninfected counterparts. Consistent with
observations that Th17 cells are among the major producers
of TNF,22,23 there was a strong association between the IL-17A
and TNF-producing alveolar CD4+ T cells (data not shown).
However, we found no association between the relative abso-
lute counts of IL-17A/TNF-producing CD4+ T cells with periph-
eral blood CD4+ T cell count. Furthermore, the absolute
counts of IL-17A/TNF-producing CD4+ T cells were higher in
the ART-treated HIV-infected adults compared to the HIV-
uninfected controls. These ﬁndings suggest that the increase
in Th17 responses against S. pneumoniae in ART-treated
individuals is unlikely due to general reconstitution of CD4+ T
cells. On the other hand, this might be an immune reconsti-
tution inﬂammatory syndrome (IRIS)-like phenomenon, which
occurs in some individuals on ART and is associated with an
overwhelming response to a previously acquired infection.24,25
Pneumococcal carriage in humans is immunising and leads
to increased frequency of pneumococcal-speciﬁc IL17-
producing CD4+ T cells in the lung.11 The level of pneumo-
coccal exposure is relatively high inMalawi,with pneumococcal
carriage rates between 15–45%15,16,26 in adults and 45–60% in
children.27,28 The preservation of the IL-17A/TNF/IFN-γ pro-
ducing alveolar CD4+ T cell responses against S. pneumoniae
in HIV-infected adults may be due to this high degree of
mucosal pneumococcal exposure. Previous studies fromMalawi
have reported higher nasopharyngeal pneumococcal car-
riage rates in ART-treated HIV-infected adults (41–52%) com-
pared to HIV-uninfected individuals (13–14%) and untreated
HIV-infected adults (19–27%).15,16 It is therefore plausible
that the increased proportions of IL-17A and TNF-producing
alveolar CD4+ T cells responding to pneumococcal CCS in
ART-treated HIV-infected adults might be a reﬂection of the
increased mucosal pneumococcal exposure.
The potential limitation of our study is that the two HIV-
infected groups (ART-naïve and treated) were female biased
compared to the HIV-uninfected group, however, analysis of
the alveolar CD4+ T cell responses based on gender did not
show any statistically signiﬁcant differences among the groups
(data not shown). The other limitation of the study is that
wemeasured the CD4+ T cell responses against S. pneumoniae
in vitro,which might not accurately represent the behaviour
of these cells in vivo. However, this approach allowed us to
ascertain the presence or absence of pneumococcal-speciﬁc
alveolar Th17 cells in HIV-infected adults capable of produc-
ing IL-17A, TNF and IFN-γ upon stimulation with pneumococ-
cal antigens.
In conclusion, we have found that alveolar Th17 responses
against S. pneumonia are preserved in HIV-infected adults.
This suggests that there might be other alternative mecha-
nisms rendering HIV-infected individuals more susceptible
to pneumococcal pneumonia. Serotype-independent T cell-
based pneumococcal vaccines that focus solely on inducing a
robust Th17 response may not promote clearance of lung
infection and prevent pneumonia in HIV-infected adults, up
and above naturally-acquired immunity in the alveolar space,
since these individuals already posses robust pneumococcal-
speciﬁc alveolar Th17 cells.We recommend that future studies
should examine these Th17 responses in individuals with
pneumococcal pneumonia to ascertain their role in humans.
Methods
Subjects
The study was conducted at the Queen Elizabeth Central
Hospital, a large teaching hospital in Blantyre, Malawi. Par-
ticipants were recruited from the hospital’s voluntary coun-
selling and testing (VCT) and ART clinics. They were healthy,
asymptomatic adults (≥18yrs), comprising HIV-1-uninfected
and HIV-1-infected volunteers with no clinical evidence of
active disease, willing to undergo bronchoscopy and
bronchoalveolar lavage (BAL) for research purposes.29 HIV
testing was performed on whole blood using two commercial
point-of-care rapidHIV test kits, DetermineHIV 1/2 kit (Abbott
Diagnostic Division) and Unigold HIV 1/2 kit (Trinity Biotech
Inc.). A participant was considered HIV-uninfected if the
test was negative by both kits or HIV-infected if the test was
positive by both kits. If Determine and Unigold results were
discordant, a third rapid test using Bioline HIV 1/2 kit
(Standard Diagnostics Inc.) was performed to resolve the
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discordance. HIV infected individuals were commenced on
ART according to the Malawi standardised national proto-
cols: WHO stage III/IV disease or CD4 count of ≤350 (the
cut-off used in Malawi at the time of study recruitment).
None of the participants had received pneumococcal vacci-
nation prior to joining the study. The research ethics com-
mittee of the Malawi College of Medicine approved the study
and all participants provided written-informed consent.
HIV-1-infected participants were divided into two sub-
groups based on whether they were on ART or not at the time
of recruitment. First line ART consisted of stavudine,
lamivudine, and nevirapine, or tenofovir, lamivudine, and
efavirenz (following a change in the national guidelines in
2011). Exclusion criteria for the studywere: current or history
of smoking, prior history of pneumococcal disease or pulmo-
nary TB, use of immunosuppressive drugs, severe anaemia
(Hb <8g/dl) and known or suspected pregnancy. Peripheral
blood CD4+ T cell counts were measured in all participants
while HIV plasma viral load measurements were performed
in HIV-infected participants only. HIV-1 RNA levels in blood
plasmaweremeasured using the Abbot Real-Time HIV-1 assay
with a lower limit of detection of 150 copies/mL (Abbott
Molecular, Germany), per the manufacturer’s instructions.
Collection and processing of BAL ﬂuid and blood
samples
BAL ﬂuid samples were collected at bronchoscopy and pro-
cessed as previously described.8,30 Non adherent cells, which
consist mainly of lymphocytes, were enriched by adherence
of macrophages to plastic,17 and were used to assess the
frequency of antigen-speciﬁc CD4+ T cells. Peripheral blood
sampleswere also collected fromparticipants. Plasma samples
were used for measurements of HIV viral load.
Intracellular cytokine staining
Antigen-speciﬁc CD4+ T cell responses were measured as
previously described.8 In brief, non-adherent BAL cells
(0.5x106cells/well) suspended in 200 µl of complete media
were cultured in 96 well plates and stimulated with pneu-
mococcal cell culture supernatant (8 µg/ml) (prepared from
a standard encapsulated type 2 (D39) S. pneumoniae strain
as previously described16,31). The cell culture supernatant
has been previously utilised to probe pneumococcal-speciﬁc
T cell immunity,8,15,16,31 is rich in pneumococcal surface pro-
teins and pneumolysin.31 Cells were stained with Violet Via-
bility dye (LIVE/DEAD® Fixable Dead Cell Stain kit, Invitrogen,
UK), surfacemarkers (anti-CD3 PE-Cy5, anti-CD4 APC-H7 and
anti-CD8 PE-Cy7 antibodies, all from BD Bioscience, UK), and
intracellular markers (anti-IFN-γ APC, anti-tumour necrosis
factor (TNF) Alexa Fluor 488 and anti-IL17 PE antibodies, all
from BD Bioscience, UK). Approximately 50,000 events were
acquired in the CD4+ gate using a CyAn ADP 9-colour ﬂow
cytometer (Beckman Coulter, USA). Flow cytometry data
were analysed using FlowJo software (TreeStar, USA).
Statistical analyses
Statistical analyses and graphical presentation were per-
formed using GraphPad Prism 5 (GraphPad Software, USA) or
PESTLE 1.7 and SPICE 5.3 (both NIAID, USA). The programs
PESTLE and SPICE were kindly provided by Mario Roederer,
Vaccine Research Center, NIAID, NIH. Flow cytometry data
were analysed using Kruskal-Wallis test and Dunn’s multiple
comparisons test. Results are given asmedian and interquartile
range (IQR). Correlations were measured using Spearman’s
test. Differenceswere considered statistically signiﬁcantwhen
p < 0.05.
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